• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors

by MM360 Staff | Apr 17, 2025 | Uncategorized

Source: CureToday articles Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery. Read More

Raising Awareness on Multidisciplinary Approaches in GI Cancers

by MM360 Staff | Apr 17, 2025 | Uncategorized

Source: CureToday articles Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as per an expert. Read More

Optimizing Oncology Clinical Pathways at the Point of Care

by MM360 Staff | Apr 17, 2025 | Uncategorized

Source: ASCO Daily News Dr. John Sweetenham, Dr. Larry Shulman, and Dr. Rebecca Maniago discuss the integration of clinical pathways and decision support tools into the cancer center workflow, challenges to implementation at the point of care, and the promise of AI to...

FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC. Read More

Breaking Down The Use of Rina-S in Advanced Ovarian Cancer

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer. Read More

TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT